Material Agreements

Hess Midstream LP entered into Unit Repurchase Agreement with Hess Investments North Dakota LLC and GIP II Blue Holding, L.P. valued at approximately $100 million (effective 2024-03-11).

“On March 11, 2024, Hess Midstream LP, a Delaware limited partnership (the “Company”), Hess Midstream Operations LP, a Delaware limited partnership and a subsidiary of the Company that holds all of the Company’s operating assets (“HESM OpCo” and, together with the Company, the “Partnership Entities”), Hess Investments North Dakota LLC, a Delaware limited liability company (“HINDL”), and GIP II Blue Holding, L.P., a Delaware limited partnership (“GIP” and, together with HINDL, the “Sponsors” and each, a “Sponsor”), entered into a Unit Repurchase Agreement (the “Repurchase Agreement”) pursuant to which HESM OpCo agreed to purchase from (a) HINDL 1,059,390 Class B units representing limited partner interests in HESM OpCo (the “Class B Units”) and (b) GIP 1,757,511 Class B Units (such Class B Units subject to the Repurchase Agreement, the “Repurchased Units”) for an aggregate purchase price of approximately $100 million (the “Repurchase Transaction”).”

Odyssey Semiconductor Technologies, Inc. entered into Promissory Notes with Nina and John Edmunds 1998 Family Trust valued at a secured convertible promissory note in the amount of $250,000 and a secured convertible promissory (effective 2024-03-14).

“On March 14, 2024, Odyssey Semiconductor Technologies, Inc. (the “Company”) issued a secured convertible promissory note in the amount of $250,000 and a secured convertible promissory note in the amount of $184,000 (the “Promissory Notes”), respectively, to the Nina and John Edmunds 1998 Family Trust dated January 27, 1998 (the “Edmunds Trust”), of which the Company’s Chairman, John Edmunds, is the trustee.”

Unicycive Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Aggregate purchase price of $50 million for 50,000 shares of Series B Convertible Preferred Stock at (effective 2024-03-13).

“On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), 50,000 shares of its Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share with an initial conversion price of $1.00 per share, subject to adjustment (the “ Conversion Price”) , for an aggregate purchase price of $50 million.”

Unicycive Therapeutics, Inc. entered into Exchange Agreement with certain accredited investors (effective 2024-03-13).

“On March 13, 2024, Unicycive Therapeutics , Inc. (the “ Company ”) entered into an exchange agreement (the “ Exchange Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Investors surrendered an aggregate of 43,649,000 shares of Series A-2 Preferred Stock held by them in exchange for an aggregate of 21,388.01 shares of new preferred stock to be known as “Series A-2 Prime Preferred””

AppLovin Corp amended Amendment No. 10 with Bank of America, N.A. valued at $1,463,750,000 (effective 2024-03-14).

“On March 14, 2024, AppLovin Corporation (“AppLovin” or “Company”) entered into Amendment No. 10 (“Amendment No. 10”) to that certain Credit Agreement, dated as of August 15, 2018, by and among AppLovin, as borrower, Bank of America, N.A., as administrative agent and collateral agent, and the other parties thereto”

Acushnet Holdings Corp. entered into a equity purchase with Magnus Holdings Co., Ltd. valued at $37.5 million (effective 2024-03-14).

“On March 14, 2024, in connection with its existing $1.0 billion share repurchase authorization, Acushnet Holdings Corp. (the “Company”) entered into an agreement with Magnus Holdings Co., Ltd. (“Magnus”) pursuant to which the Company will purchase up to an aggregate of $37.5 million of shares of its common stock from Magnus on a share-for-share basis as the Company repurchases shares in the open market or privately negotiated transactions.”

Cardlytics, Inc. entered into Agreement with American Express Travel Related Services Company, Inc. (effective 2024-03-14).

“On March 14, 2024, Cardlytics, Inc. (the “Company”) entered into an agreement (the “Agreement”) with American Express Travel Related Services Company, Inc. (“AXP”).”

Phunware, Inc. entered into Settlement Agreement and Release of Claims with Wilson Sonsini Goodrich & Rosati, PC valued at total sum of $2,193,852.02 (effective 2024-03-05).

“On March 5, 2024, the Company entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with WSGR settling the Uber Litigation. As part of the Settlement Agreement, the Company was required to (i) pay WSGR a total sum of $2,193,852.02 no later than March 8, 2024, (ii) file requests for dismissal of the Uber Litigation, with prejudice, with the Santa Clara Superior Court, and (iii) request that the Uber Arbitration be dismissed and closed with prejudice. In addition, WSGR is required to request that the Uber Arbitration be dismissed and closed with prejudice. The Settlement Agreement also provides that the Company and WSGR release each other from all claims that the Company or WSGR may have against one another with respect to the Uber Litigation or the Uber Arbitration. The full text of the Settlement Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.”

Red Rock Resorts, Inc. entered into Indenture with Deutsche Bank Trust Company Americas, as trustee valued at $500 million aggregate principal amount of 6.625% Senior Notes due 2032 (effective 2024-03-14).

“On March 14, 2024, Red Rock Resorts, Inc.’s consolidated subsidiary, Station Casinos LLC (the “Company”), issued $500 million aggregate principal amount of 6.625% Senior Notes due 2032 (the “Notes”) pursuant to an indenture, dated as of March 14, 2024 (the “Indenture”), among the Company, the guarantors party thereto (the “Guarantors”) and Deutsche Bank Trust Company Americas, as trustee.”

Red Rock Resorts, Inc. entered into Credit Agreement with Deutsche Bank AG Cayman Islands Branch, as administrative agent and collateral agent, and the lenders party thereto (effective 2024-03-14).

“On March 14, 2024, the Company, the subsidiary guarantors party thereto, Deutsche Bank AG Cayman Islands Branch, as administrative agent and collateral agent, and the lenders party thereto entered into an Amended and Restated Credit Agreement (the “Credit Agreement”), which amended and restated the Existing Credit Agreement and pursuant to which the Company (a) incurred (i) a new senior secured term “B” loan facility in an aggregate principal amount of $1,570.0 million (the “New Term B Facility” and the term “B” loans funded thereunder, the “New Term B Loan”) and (ii) a new senior secured revolving credit facility in an aggregate principal amount of $1,100.0 million (the “New Revolving Credit Facility” and, together with the New Term B Facility, the “New Credit Facilities”)”

PAVmed Inc. entered into Registration Rights Agreement with Series B Investors (effective 2024-03-13).

“Lucid Diagnostics and the Series B Investors also executed a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series B Preferred Stock.”

PAVmed Inc. entered into Exchange Agreement with certain accredited investors valued at 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (effective 2024-03-13).

“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), and 10,670 shares of Lucid Diagnostics’ Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), held by them for 31,790 shares of Series B Prefe”

PAVmed Inc. entered into Series B Subscription Agreement with certain accredited investors valued at 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value (effective 2024-03-13).

“On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share”

PAVmed Inc. amended Amendment and Waiver with holder of senior secured convertible notes valued at $2,000,000 cash payment; maturity extended to April 4, 2025 (April 2022 Note) and September 8, 2025 (effective 2024-03-12).

“Effective as of March 12, 2024, PAVmed Inc. (the “ Company ”), entered into an amendment and waiver (the “ Amendment and Waiver ”) with the holder of the senior secured convertible note issued by the Company as of April 4, 2022 (the “ April 2022 Note ”) and the secured convertible note issued by the Company as of September 8, 2022 (the “ September 2022 Note ,” and together with the April 2022 Note, the “ Notes ”).”

GridAI Technologies Corp. entered into Merger Agreement with ImmunogenX.

“Pursuant to the terms of the Merger Agreement, we are required to recommend that our stockholders approve the conversion of shares of our Series G Preferred Stock into shares of our Common Stock.”

Oportun Financial Corp entered into Amendment No. 3 to the Credit Agreement (Third Amendment) with certain affiliates of Neuberger Berman Specialty Finance as lenders, and Wilmington Trust, National Association, as administrative agent and collateral agent valued at Modifies minimum asset coverage ratio covenant levels, provides for an interest rate step-up of 3.00 (effective 2024-03-12).

“On March 12, 2023, the Company entered into an Amendment No. 3 to the Credit Agreement (the “Third Amendment”), by and among the Company, as borrower, the subsidiaries of the Company party thereto as guarantors, certain affiliates of Neuberger Berman Specialty Finance as lenders, and Wilmington Trust, National Association, as administrative agent and collateral agent (the “Agent”), which amended the Credit Agreement, dated as of September 14, 2022, as amended, by and among the Company, the lenders from time to time party thereto and the Agent.”

Oportun Financial Corp entered into Eighth Amendment to the Indenture (Eighth RF Indenture Amendment) with Wilmington Trust, National Association valued at Provides for a three-month principal payment holiday for March, April and May 2024 in amounts equal (effective 2024-03-08).

“On March 8, 2024, Oportun RF, LLC (the “RF Issuer”), a subsidiary of Oportun Financial Corporation (the “Company”), and Wilmington Trust, National Association, as indenture trustee, securities intermediary and depositary bank, entered into the Eighth Amendment to the Indenture (the “RF Indenture”) dated December 20, 2021 (the “Eighth RF Indenture Amendment”), and other related documents (together with the Eighth RF Indenture Amendment, the “Eighth RF Amendment”) related to the Company’s asset-backed variable funding facility secured by certain residual cash flows from the Company’s securitizations.”

Rezolute, Inc. entered into Exchange Agreement with certain Company stockholders valued at aggregate of 3,000,000 shares of common stock (effective 2024-03-08).

“On March 8, 2024, Rezolute, Inc. (the “Company”) entered into a securities exchange agreement (the “Exchange Agreement”) with certain Company stockholders (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 3,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Retired Shares”), owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 3,000,000 shares of common stock”

Regulus Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at total gross proceeds of approximately $100.0 million (effective 2024-03-11).

“On March 11, 2024, Regulus Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company sold and issued (i) 45,108,667 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $1.60 per share and (ii) 173,915 shares of the Company’s newly designated non-voting Class A-6 convertible preferred stock, par value $0.001 per share (the “Class A-6 Convertible Preferred Stock”), in lieu of shares of Common Stock, at a purchase price of $160.00 per share in a private placement transaction (the “Private Placement”), which closed on March 14, 2024 (the “Closing”).”

OptiNose, Inc. entered into Manufacturing and Supply Agreement with Hikma Pharmaceuticals USA, Inc. valued at Manufacturing and Supply Agreement for XHANCE units; minimum purchase obligations; term through Dece (effective 2020-12-11).

“OptiNose, Inc. (“Optinose”) and Hikma Pharmaceuticals USA, Inc. (“Hikma”) are parties to a Manufacturing and Supply Agreement, dated December 11, 2020 (the “Manufacturing Agreement”) pursuant to which, following FDA approval of Hikma as an alternative manufacturing site (which occurred on March 9, 2024), Hikma will manufacture and supply finished XHANCE units.”

Vita Coco Company, Inc. entered into Manufacturing Agreement with Century Pacific Food, Inc. (effective 2024-03-08).

“On March 8, 2024, All Market Singapore PTE Ltd., a wholly owned subsidiary of The Vita Coco Company, Inc. (the “Company”), entered into a Manufacturing and Purchasing Agreement (the “Manufacturing Agreement”) with Century Pacific Food, Inc. (“Century Pacific”).”

Cartesian Therapeutics, Inc. terminated License and Development Agreement with Audentes Therapeutics, Inc. ("Astellas") (effective 2024-06-06).

“On March 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) received notice from Audentes Therapeutics, Inc. (“Astellas”) of Astellas’ termination of the License and Development Agreement, dated January 8, 2023, by and between the Company and Astellas (the “Agreement”).”

Pacific Oak Strategic Opportunity REIT, Inc. entered into Purchase and Sale Agreement and Joint Escrow Instructions with KB Home Las Vegas, Inc. and Tri Pointe Homes Nevada, Inc. valued at approximately $195 million (effective 2024-03-10).

“On March 10, 2024, Pacific Oak Strategic Opportunity REIT, Inc. (the “Company”), through two indirectly wholly-owned subsidiaries, entered into a Purchase and Sale Agreement and Joint Escrow Instructions (the “Agreement”) for the sale of 454.31 gross acres of land (“Village 2”) located in the City of North Las Vegas, Nevada to KB Home Las Vegas, Inc. and Tri Pointe Homes Nevada, Inc. (collectively, the “Buyer”), subject to certain closing conditions.”

Stablecoin Development Corp entered into Membership Unit Purchase Agreement with New Age Investments LLC valued at $1,070,000 (effective 2024-03-12).

“On March 12, 2024, NovaBay Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Membership Unit Purchase Agreement (the “ Purchase Agreement ”) by and among: (i) New Age Investments LLC, a Florida limited liability company (the “ Buyer ”); (ii) DERMAdoctor, LLC, a Missouri limited liability company (“ DERMAdoctor ”); and (iii) the Company.”

BlackRock Finance, Inc. entered into Indenture with The Bank of New York Mellon valued at $500,000,000 aggregate principal amount of 4.700% Notes due 2029, $1,000,000,000 aggregate principal (effective 2024-03-14).

“The Notes were issued under the Indenture, dated as of March 14, 2024 (the "Base Indenture"), among BlackRock Funding, BlackRock and The Bank of New York Mellon, as trustee (the "Trustee"), as amended by the First Supplemental Indenture, dated as of March 14, 2024, among BlackRock Funding, BlackRock and the Trustee (the "First Supplemental Indenture" and together with the Base Indenture, the "Indenture").”

BlackRock Capital Investment Corp amended First Amendment with the Noteholders (effective 2024-03-13).

“On March 13, 2024, BlackRock Capital Investment Corporation (the “ Company ”) entered into a first amendment (the “ First Amendment ”) to the Master Note Purchase Agreement, dated April 21, 2022”

LKQ CORP entered into Indenture with U.S. Bank Trust Company, National Association, as trustee, and Elavon Financial Services DAC, as paying agent valued at €750,000,000 aggregate principal amount (effective 2024-03-13).

“On March 13, 2024, LKQ Dutch Bond B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of The Netherlands (“LKQ Finance”), an indirect wholly-owned subsidiary of LKQ Corporation (the "Company," "we," "us," or "our"), completed an offering (the “Offering”) of €750,000,000 aggregate principal amount of LKQ Finance’s 4.125% Notes due 2031 (the “Notes”).”

ESSEX PORTFOLIO LP entered into 5.500% Senior Notes due 2034 Indenture with U.S. Bank Trust Company, National Association valued at $350,000,000 (effective 2024-03-14).

“On March 14, 2024, Essex Portfolio, L.P. (the “Operating Partnership”), the operating partnership of Essex Property Trust, Inc. (the “Company”), issued $350.0 million aggregate principal amount of its 5.500% senior notes due 2034 (the “Notes”).”

Eloxx Pharmaceuticals, Inc. entered into License Agreement with Almirall, S.A. valued at $3.0 million (effective 2024-03-11).

“entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”).”

JAKKS PACIFIC INC entered into Redemption Agreement with holders of its Series A Senior Preferred Stock valued at $35 million (effective 2024-03-08).

“On March 8, 2024, the registrant entered into a Redemption Agreement (the “Redemption Agreement”) with the holders of its Series A Senior Preferred Stock (the “Preferred Stock”). Pursuant to the terms of the Redemption Agreement, the Company redeemed all outstanding shares of the Preferred Stock for an aggregate purchase price of $35 million, consisting of $20 million of cash and 571,295 shares of its common stock ( the “Common Stock”), valued at $15 million, or $26.26 per share.”

Coterra Energy Inc. entered into Second Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 aggregate principal amount (effective 2024-03-13).

“closed its previously announced registered public offering of $500,000,000 aggregate principal amount of its 5.60% senior notes due 2034”

UMH PROPERTIES, INC. entered into Distribution Agreement with BMO Capital Markets Corp., J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, B. Riley Securities, Inc., Compass Point Research & Trading, LLC, and Janney Montgomery Scott LLC valued at $150,000,000 (effective 2024-03-12).

“(the “Company”) entered into an equity distribution agreement (the “Distribution Agreement”) with BMO Capital Markets Corp., J.P.”

KORU Medical Systems, Inc. entered into Loan and Security Agreement with HSBC Ventures USA Inc. valued at $5,000,000 (effective 2024-03-08).

“On March 8, 2024, KORU Medical Systems, Inc. (the “Company”) entered into a loan and security agreement (the “Loan and Security Agreement”), by and between the Company and HSBC Ventures USA Inc., as lender providing for a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “Revolver”) and a term loan facility in an aggregate principal amount not to exceed $5,000,000”

HUMANA INC entered into Twenty-Ninth Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2024-03-13).

“and a twenty-ninth supplemental indenture, dated as of March 13, 2024, by and between the Company and the Trustee relating to the 2054 Senior Notes (the “Twenty-Ninth Supplemental Indenture””

HUMANA INC entered into Twenty-Eighth Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2024-03-13).

“The Senior Notes were issued under an indenture dated as of August 5, 2003, by and between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor to The Bank of New York), as trustee (the “Trustee”) (the “Original Indenture”), as supplemented by a twenty-eighth supplemental indenture, dated as of March 13, 2024, by and between the Company and the Trustee relating to the 2031 Senior Notes (the “Twenty-Eighth Supplemental Indenture””

HUMANA INC entered into Underwriting Agreement with Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, PNC Capital Markets LLC and Wells Fargo Securities, LLC valued at $1,250 million aggregate principal amount of its 5.375% Senior Notes due 2031 and $1,000 million agg (effective 2024-03-11).

“On March 11, 2024, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, PNC Capital Markets LLC and Wells Fargo Securities, LLC , as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $1,250 million aggregate principal amount of its 5.375% Senior Notes due 2031 (the “2031 Senior Notes”) and $1,000 million aggregate principal amount of its 5.750% Senior Notes due 2054 (the “2054 Senior Notes” and, together with the 2031 Senior Notes, the “Senior Notes”), in accordance with the terms and conditions set forth in the Underwriting Agreement.”

T. Rowe Price OHA Select Private Credit Fund entered into Master Note Purchase Agreement with qualified institutional investors valued at $300,000,000 in aggregate principal amount of Series 2024A Senior Notes, due March 7, 2029, with a f (effective 2024-03-07).

“On March 7, 2024, T. Rowe Price OHA Select Private Credit Fund (the “Company”) entered into a Master Note Purchase Agreement (the “Note Purchase Agreement”) governing the issuance of $ 300,000,000 in aggregate principal amount of Series 2024A Senior Notes, due March 7, 2029, with a fixed interest rate of 7.77% per year (the “Notes”), to qualified institutional investors in a private placement.”

Corebridge Financial, Inc. entered into Amendment and Waiver of Consent and Voting Rights with American International Group, Inc. valued at Amendment and Waiver of Consent and Voting Rights (effective 2024-03-11).

“On March 11, 2024, Corebridge Financial, Inc. (the “Company”) entered into an Amendment and Waiver of Consent and Voting Rights (the “Amendment and Waiver”) with American International Group, Inc. (“AIG”) and certain affiliates of Argon Holdco LLC (“Argon”) and Blackstone, Inc. (“Blackstone”) that (i) amends the Stockholders Agreement, dated as of November 2, 2021, between the Company, AIG and Argon such that Argon shall have no right to consent to any repurchase of shares of common stock of the Company, par value $0.01 per share (“Common Stock”) if such repurchase would result in Argon owning, of record, more than 9.9% of the then-outstanding Common Stock, provided that , no such repurchase will be permitted if it would result in Argon owning, of record, more than 14.9% of the then-outstanding Common Stock and (ii) waives the right of Argon, Blackstone and certain of their affiliates to vote or act by written consent with respect to any shares of Common Stock owned by them from time t”

MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.4 million (effective 2024-03-11).

“On March 11, 2024, MAIA Biotechnology, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 2,043,587 shares (the "Investor Shares") of the Company’s common stock, par value $0.0001 per share (" Common Stock "), and (ii) warrants (the " Investor Warrants ") to purchase up to 2,043,587 shares of the Company’s Common Stock, at a price per share of $1.17 for an aggregate purchase price of approximately $2.4 million.”

Bite Acquisition Corp. amended Business Combination Agreement with Above Food Corp. (effective 2024-03-12).

“On March 12, 2024, Bite, Above Food, TopCo and Merger Sub entered into an amendment to the Business Combination Agreement ("Amendment No. 1")”

Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).

“On March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited (the “ Bookrunner ” or “ Stifel ”), pursuant to which the Company agreed to allot and issue new ordinary shares, nominal value £0.0025 per ordinary share (the “ Placing Shares ”) to certain investors (the “ Placees ”) in an unregistered offering (the “ Private Placement ”), up to an aggregate of 46,801,872 ordinary shares.”

BTC Digital Ltd. entered into Acquisition Agreement with Alpha Plotter, LLC valued at $3.4 million (effective 2024-03-09).

“On March 9, 2024, and Meten Service USA Corp. (“Meten”), a wholly owned subsidiary of BTC Digital Ltd. (the “Company”), entered into an acquisition and purchase agreement (the “Acquisition Agreement”) with Alpha Plotter, LLC (the “Seller”) to acquire the Seller’s BTC mining facility under construction in North Carolina (the “Facility”).”

John Deere Receivables LLC entered into Underwriting Agreement with the underwriters valued at Underwriting Agreement for asset-backed securities issued by John Deere Owner Trust 2024 (effective 2024-03-11).

“Item 1.01 Entry into a Material Definitive Agreement . In connection with the issuance by John Deere Owner Trust 2024 (the “ Trust ” ) of the asset-backed securities (the “ Notes ” ) described in the Prospectus, dated March 11, 2024 (the “ Prospectus ” ), which was filed with the Securities and Exchange Commission pursuant to its Rule 424(b)(5) by John Deere Receivables LLC (the “ Registrant ” or the “ Depositor ” ), the Depositor entered into an Underwriting Agreement on March 11, 2024 (the “ Underwriting Agreement ” ) with the underwriters listed in”

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with several institutional and accredited investors (effective 2024-03-08).

“On March 8, 2024, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors”

Synchrony Card Funding, LLC entered into Class A(2024-1) Underwriting Agreement with Wells Fargo Securities, LLC, Barclays Capital Inc. and SG Americas Securities, LLC (effective 2024-03-11).

“On March 11, 2024, Synchrony Card Funding, LLC (“ Funding ”) and Synchrony Bank entered into an Underwriting Agreement by and among Funding, Synchrony Bank, Wells Fargo Securities, LLC, Barclays Capital Inc. and SG Americas Securities, LLC (the “ Class A(2024-1) Underwriting Agreement ”)”

Limbach Holdings, Inc. amended First Amendment to the Second A&R Wintrust Credit Agreement with Wheaton Bank & Trust Company, N.A., a subsidiary of Wintrust Financial Corporation (effective 2024-03-13).

“On March 13, 2024, Limbach Facility Services LLC, Limbach Holdings LLC and other designated loan parties entered into a first amendment to the second amended and restated Wintrust credit agreement (the “First Amendment to the Second A&R Wintrust Credit Agreement”) with the lenders party thereto and Wheaton Bank & Trust Company, N.A., a subsidiary of Wintrust Financial Corporation (collectively, “Wintrust”), as administrative agent.”

Evolus, Inc. entered into Underwriting Agreement with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A valued at approximately $46.9 million (effective 2024-03-11).

“On March 11, 2024, Evolus, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A thereto (together, the “Underwriters”), in connection with the underwritten public offering, issuance and sale by the Company (the “Offering”) of 3,554,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”).”

Delek Logistics Partners, LP entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $650,000,000 (effective 2024-03-13).

“On March 13, 2024, Delek Logistics Partners, LP, a Delaware limited partnership (the “Partnership”), Delek Logistics Finance Corp., a Delaware corporation and a wholly owned subsidiary of the Partnership (“Finance Corp.” and together with the Partnership, the “Issuers”), the Partnership’s existing subsidiaries (other than Finance Corp., the “Guarantors”) and U.S. Bank Trust Company, National Association, as trustee, entered into an indenture (the “Indenture”), pursuant to which the Issuers issued $650,000,000 in aggregate principal amount of 8.625% senior notes due 2029 (the “2029 Notes”).”

Empire State Realty Trust, Inc. amended Third Amendment to that certain Credit Agreement, dated as of March 19, 2020 with Wells Fargo Bank, National Association, as administrative agent, and the lenders party thereto (effective 2024-03-13).

“On March 13, 2024, the Operating Partnership and the Company entered into a Third Amendment to that certain Credit Agreement, dated as of March 19, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “ WF Credit Agreement ”) among the Company, the Operating Partnership, the lenders party thereto from time to time and Wells Fargo Bank, National Association, as administrative agent.”

Empire State Realty Trust, Inc. amended Second Amended and Restated Credit Agreement with Bank of America, N.A., as administrative agent, Wells Fargo Bank, National Association and JPMorgan Chase Bank, N.A., as co-syndication agents, and the lenders and the letter of credit issuers party thereto valued at $620 million senior unsecured revolving credit facility and a $95 million term loan facility (effective 2024-03-08).

“On March 8, 2024, Empire State Realty OP, L.P. (the “ Operating Partnershi p”) and its general partner, Empire State Realty Trust, Inc. (the “ Company ”) entered into a Second Amended and Restated Credit Agreement (the “ BofA Credit Agreement ”) with Bank of America, N.A., as administrative agent, Wells Fargo Bank, National Association and JPMorgan Chase Bank, N.A., as co-syndication agents, and the lenders and the letter of credit issuers party thereto.”